Combined use of long-acting insulin analogue, GLP-1 receptor agonist, and sulfonylurea in type 2 diabetes

Combined use of long-acting insulin analogue, GLP-1 receptor agonist, and sulfonylurea in type 2 diabetes - Combined use of long-acting insulin analogue, GLP-1 receptor agonist, and sulfonylurea in type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017912

Enrollment

Registered

2015-06-15

Start date

2015-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

To switch to the combination therapy of a long-acting insulin, a GLP-1 receptor agonist liraglutide, and a sulfonylurea glimepiride To continue the combination therapy of a long-acting insulin and mul

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients treated with the combined therapy of a long-acting insulin analogue and multiple oral hypoglycemic agents including a sulfonylurea, a DPP-4 inhibitor and metformin

Exclusion criteria

Exclusion criteria: - Patients with severe hepatic, renal, and/or cardiac disease - Patients with hypersentitivity to the agents used in the current study - Patients who are pregnant, breast-feeding or may become pregnant - Patients who are judged by the investigator to be inappropriate for this study for any other reason.

Design outcomes

Primary

Measure	Time frame
Diabetes therapy-related QOL	—

Secondary

Measure	Time frame
- Medication adherance - Hemoglobin A1c, Blood glucose - Body weight - safety - Cost	—

Countries

Japan

Contacts

Public ContactToshihiko Shiraiwa

Shiraiwa Medical Clinic Shiraiwa Medical Clinic

takahara@endmet.med.osaka-u.ac.jp072-971-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026